UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/656,894	09/08/2003	Michael A. Whitt	P-3558-US	1535	
	7590 07/02/200 dek Latzer, LLP	EXAMINER			
1500 Broadway 12th Floor		MARVICH, MARIA			
New York, NY	10036	ART UNIT	PAPER NUMBER		
			1633		
			MAIL DATE	DELIVERY MODE	
			07/02/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/656,894	WHITT ET AL.	
Examiner	Art Unit	
MARIA B. MARVICH	1633	

	MARIA B. MARVICH	1633				
The MAILING DATE of this communication appea	rs on the cover sheet with the c	correspondence add	ress			
THE REPLY FILED 13 May 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.						
1. The reply was filed after a final rejection, but prior to or on the application, applicant must timely file one of the following reapplication in condition for allowance; (2) a Notice of Appear for Continued Examination (RCE) in compliance with 37 CF periods:	ne same day as filing a Notice of A plies: (1) an amendment, affidavi Il (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request			
 a) The period for reply expires 6 months from the mailing date o b) The period for reply expires on: (1) the mailing date of this Adno event, however, will the statutory period for reply expire late 	visory Action, or (2) the date set forth					
Examiner Note: If box 1 is checked, check either box (a) or (b) MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).). ONLY CHECK BOX (b) WHEN THE	•				
Extensions of time may be obtained under 37 CFR 1.136(a). The date or have been filed is the date for purposes of determining the period of extered under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shipset forth in (b) above, if checked. Any reply received by the Office later the may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	n which the petition under 37 CFR 1.1 nsion and the corresponding amount or ortened statutory period for reply origi	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as			
2. The Notice of Appeal was filed on <u>13 December 2007</u> . A buthe date of filing the Notice of Appeal (37 CFR 41.37(a)), or appeal. Since a Notice of Appeal has been filed, any reply MENDMENTS	any extension thereof (37 CFR 4	1.37(e)), to avoid disn	nissal of the			
3. The proposed amendment(s) filed after a final rejection, but	ut prior to the date of filing a brief,	will not be entered be	cause			
 (a) ☐ They raise new issues that would require further cons (b) ☐ They raise the issue of new matter (see NOTE below 	•	ΓE below);				
(c) They are not deemed to place the application in bette appeal; and/or	•	ducing or simplifying th	ne issues for			
(d) They present additional claims without canceling a co		ected claims.				
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.116						
 4. The amendments are not in compliance with 37 CFR 1.121 5. Applicant's reply has overcome the following rejection(s): _ 		mpliant Amendment (F	PTOL-324).			
Mewly proposed or amended claim(s) would be allow non-allowable claim(s).		timely filed amendmer	nt canceling the			
7. For purposes of appeal, the proposed amendment(s): a) know the new or amended claims would be rejected is provided in the control of the c		l be entered and an ex	xplanation of			
The status of the claim(s) is (or will be) as follows: Claim(s) allowed:						
Claim(s) objected to: Claim(s) rejected: <u>1-8,15,16,18,30-37,42-45,47,49,50,57-60</u>		d 00 110				
Claim(s) withdrawn from consideration: <u>9-14,19-29,38-41,4</u> <u>AFFIDAVIT OR OTHER EVIDENCE</u>	0,40,51-50,04-74,70,70,00-00 am	<u>a 92-112</u> .				
8. The affidavit or other evidence filed after a final action, but I because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).						
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to over showing a good and sufficient reasons why it is necessary a	ercome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a			
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	of the status of the claims after er	ntry is below or attache	ed.			
11. The request for reconsideration has been considered but on See Continuation Sheet.	does NOT place the application in	condition for allowand	ce because:			
 12. ☐ Note the attached Information Disclosure Statement(s). (P 13. ☒ Other: See Continuation Sheet. 	TO/SB/08) Paper No(s)					
		/Maria B Marvich, I Primary Examiner,				

Continuation of 3. NOTE: Claim 45 has been amended such that it is drawn to a nucleic acid encoding a VSV genome wherein the genome "consists" of a deletion in amino acids 440-449 or 449-462. Hence, the scope of the claims have been amended from a nucleic acid "comprising" these mutations to one "consisting" thereof. The rejections are meant to overcome the art rejections under 35 USC 102. However, the change in scope necessitates a new search and consideration for new matter as well as art. Furthermore, the claim amendment necessitates new consideration of 112 second as it is not clear how a genome can consist of a deletion. Quite literally, this means the genome is a deletion and nothing more.

Continuation of 11. does NOT place the application in condition for allowance because: Applicants' arguments are moot in view of the non-entry of the amendment. However, it is noted that had applicants' amendment been entered, the objections to claims 5 and 34 would have been overcome. Applicants' argue that claims 59 and 81 have been cancelled, thus obviating the need to amend these claims. However, claims 59 and 81 are not indicated as cancelled. Hence, the claim objections would not have been overcome. As well, the rejection of claims 6, 35, 47, 77 and 82 under 35 USC 112, first paragraph would have been overcome by amendment limiting the M and G proteins to that from VSV. Finally, the rejections under 35 USC 102 would have been overcome.

Continuation of 13. Other: Applicants arguments for entry of the amendment filed 5/13/08 have been considered but are not persuasive for the following reasons. The MPEP teaches as guidance, "The following types of amendments are ordinarily denied entry:

(A) An amendment presenting an unpatentable claim, or a claim requiring a new search or otherwise raising a new issue in an application whose prosecution before the primary examiner has been closed." In this case as set forth above, the claims are not patentable as new issues and new considerations are necessary based upon the amendment.